Trial Profile
A phase II randomized study evaluating the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2009
Price :
$35
*
At a glance
- Drugs ABT 510 (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Therapeutic Use
- 16 Sep 2005 New trial record.